<DOC>
	<DOCNO>NCT00140478</DOCNO>
	<brief_summary>The purpose study determine effect ( good bad ) mifepristone patient androgen independent prostate cancer .</brief_summary>
	<brief_title>Mifepristone ( RU-486 ) Androgen Independent Prostate Cancer</brief_title>
	<detailed_description>Patients receive mifepristone , 200mg orally day . One treatment cycle 28 day long . Patients remain treatment unless cancer get bad develop intolerable side effect . At end cycle physical examination , routine blood test , hormone level perform . After every 3 cycle , one follow perform : bone scan , chest x-ray , CT scan MRI .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Mifepristone</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Histologic documentation adenocarcinoma prostate Bone metastasis ( e ) bone scan cat scan Clinical , biochemical , radiographic progression primary androgen ablation either orchiectomy gonadotropin release hormone analog therapy . One prior chemotherapy treatment allow . &gt; 3 week since major surgery &gt; 4 week since radiotherapy &gt; 8 week since prior strontium89 samarium 153 ECOG performance status 0 1 Absolute neutrophil count ( ANC ) &gt; 1,500/ul Platelets &gt; 100,000/ul Bilirubin &lt; 1.5 x upper limit normal ( ULN ) AST ALT &lt; 3 x ULN Creatinine &lt; 1.5 x ULN Electrolytes within 10 % normal range Serum testosterone &lt; 50ng/dL Prostatespecific antigen ( PSA ) &gt; 5.0ng/ml Concomitant therapy corticosteroid Chemotherapy within 28 day Currently active second malignancy nonmelanoma skin cancer Baseline adrenal insufficiency require longterm steroid</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Androgen Independent Prostate Cancer</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Mifepristone</keyword>
	<keyword>RU-486</keyword>
</DOC>